Liao M, Yao D, Wu L, Luo C, Wang Z, Zhang J
Acta Pharm Sin B. 2024; 14(3):953-1008.
PMID: 38487001
PMC: 10935242.
DOI: 10.1016/j.apsb.2023.12.003.
Przywara K, Adamski R, Ksiazczyk M, Suchodolski J, Cal M
Arch Microbiol. 2024; 206(4):153.
PMID: 38472387
DOI: 10.1007/s00203-024-03894-9.
Zhang W, Lang R
Front Cell Dev Biol. 2023; 11:1266973.
PMID: 37808079
PMC: 10556696.
DOI: 10.3389/fcell.2023.1266973.
Chen Y, Wu J, Zhang S, Gao W, Liao Z, Zhou T
Cell Death Dis. 2022; 13(9):803.
PMID: 36127325
PMC: 9489716.
DOI: 10.1038/s41419-022-05239-0.
Aria H, Rezaei M, Nazem S, Daraei A, Nikfar G, Mansoori B
Front Immunol. 2022; 13:947885.
PMID: 36072596
PMC: 9444135.
DOI: 10.3389/fimmu.2022.947885.
Cytoskeleton disruption by the metabolic inhibitor 3-bromopyruvate: implications in cancer therapy.
Azevedo-Silva J, Tavares-Valente D, Almeida A, Queiros O, Baltazar F, Ko Y
Med Oncol. 2022; 39(9):121.
PMID: 35716210
DOI: 10.1007/s12032-022-01712-0.
Novel mutation in hexokinase 2 confers resistance to 2-deoxyglucose by altering protein dynamics.
Hellemann E, Walker J, Lesko M, Chandrashekarappa D, Schmidt M, ODonnell A
PLoS Comput Biol. 2022; 18(3):e1009929.
PMID: 35235554
PMC: 8920189.
DOI: 10.1371/journal.pcbi.1009929.
Glioblastoma: Relationship between Metabolism and Immunosuppressive Microenvironment.
Hernandez A, Domenech M, Munoz-Marmol A, Carrato C, Balana C
Cells. 2021; 10(12).
PMID: 34944036
PMC: 8700075.
DOI: 10.3390/cells10123529.
Translating a radiolabeled imaging agent to the clinic.
Griffiths G, Vasquez C, Escorcia F, Clanton J, Lindenberg L, Mena E
Adv Drug Deliv Rev. 2021; 181:114086.
PMID: 34942275
PMC: 8889912.
DOI: 10.1016/j.addr.2021.114086.
Biodegradable reduce expenditure bioreactor for augmented sonodynamic therapy via regulating tumor hypoxia and inducing pro-death autophagy.
Zou W, Hao J, Wu J, Cai X, Hu B, Wang Z
J Nanobiotechnology. 2021; 19(1):418.
PMID: 34903226
PMC: 8670251.
DOI: 10.1186/s12951-021-01166-y.
Drug resistance and combating drug resistance in cancer.
Wang X, Zhang H, Chen X
Cancer Drug Resist. 2021; 2:141-160.
PMID: 34322663
PMC: 8315569.
DOI: 10.20517/cdr.2019.10.
Mitochondrial Function Are Disturbed in the Presence of the Anticancer Drug, 3-Bromopyruvate.
Cal M, Matyjaszczyk I, Filik K, Ogorek R, Ko Y, Ulaszewski S
Int J Mol Sci. 2021; 22(12).
PMID: 34205737
PMC: 8235118.
DOI: 10.3390/ijms22126640.
Inhibitory Effects of Epipolythiodioxopiperazine Fungal Metabolites on Isocitrate Lyase in the Glyoxylate Cycle of .
Hwang J, Chung B, Kwon O, Park S, Cho E, Oh D
Mar Drugs. 2021; 19(6).
PMID: 34067454
PMC: 8224697.
DOI: 10.3390/md19060295.
Metabolic Classification and Intervention Opportunities for Tumor Energy Dysfunction.
Monferrer E, Vieco-Marti I, Lopez-Carrasco A, Farinas F, Abanades S, de la Cruz-Merino L
Metabolites. 2021; 11(5).
PMID: 33922558
PMC: 8146396.
DOI: 10.3390/metabo11050264.
The Suppressive Effect of Butyrate and Bromopyruvate on Inflammatory Cytokine Production and Short Chain Fatty Acid Receptor Expression by Blood Mononuclear Cells in Patients with Behçet's Disease.
Yun S, Kim K, Lee E, Park S
Ann Dermatol. 2021; 30(5):566-574.
PMID: 33911480
PMC: 7992490.
DOI: 10.5021/ad.2018.30.5.566.
Metabolic Strategies for Inhibiting Cancer Development.
Icard P, Loi M, Wu Z, Ginguay A, Lincet H, Robin E
Adv Nutr. 2021; 12(4):1461-1480.
PMID: 33530098
PMC: 8321873.
DOI: 10.1093/advances/nmaa174.
Delphinidin Increases the Sensitivity of Ovarian Cancer Cell Lines to 3-Bromopyruvate.
Pienkowska N, Bartosz G, Furdak P, Sadowska-Bartosz I
Int J Mol Sci. 2021; 22(2).
PMID: 33445795
PMC: 7828231.
DOI: 10.3390/ijms22020709.
Glycolytic inhibition: an effective strategy for developing calorie restriction mimetics.
Ingram D, Roth G
Geroscience. 2020; 43(3):1159-1169.
PMID: 33184758
PMC: 8190254.
DOI: 10.1007/s11357-020-00298-7.
The Anticancer Drug 3-Bromopyruvate Induces DNA Damage Potentially Through Reactive Oxygen Species in Yeast and in Human Cancer Cells.
Cal M, Matyjaszczyk I, Litwin I, Augustyniak D, Ogorek R, Ko Y
Cells. 2020; 9(5).
PMID: 32397119
PMC: 7290944.
DOI: 10.3390/cells9051161.
Effect of methyl jasmonate and 3-bromopyruvate combination therapy on mice bearing the 4 T1 breast cancer cell line.
Yousefi S, Darvishi P, Yousefi Z, Pourfathollah A
J Bioenerg Biomembr. 2020; 52(2):103-111.
PMID: 31960257
DOI: 10.1007/s10863-019-09811-w.